• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

普通狨猴急性给予1-甲基-4-苯基-1,2,3,6-四氢吡啶后神经系统形态学变化的演变与分布

The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

作者信息

Gibb W R, Terruli M, Lees A J, Jenner P, Marsden C D

机构信息

Department of Neuropathology, National Hospitals for Nervous Diseases, Maida Vale, London.

出版信息

Mov Disord. 1989;4(1):53-74. doi: 10.1002/mds.870040109.

DOI:10.1002/mds.870040109
PMID:2494438
Abstract

Six young adult marmosets received 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in multiple doses (total 8-16 mg/kg over 2-13 days) sufficient to produce a parkinsonian syndrome and were killed up to 3.5 months later. Cellular changes were found in the substantia nigra, ventral tegmental area, and hypothalamus. The earliest histological abnormalities were axonal swellings in proximal parts of nigrostriatal axons. Subsequent changes in the substantia nigra were reduced Nissl staining, reduced cell volume, and aggregation and loss of melanin granules. Other effects were reduced nuclear and nucleolar volumes, depletion of cells, and hyperplasia of glial cells. Shrunken cytoplasm and nuclei stained uniformly with eosin, and no cells showed cytoplasmic swellings or inclusions. These cellular alterations, with nuclear changes resembling karyolysis, do not occur in Parkinson's disease, which is characterised by Lewy body inclusions and signs of chromatolysis. The rapid appearance of axonal swellings, disruption of Nissl substance, and cell shrinkage suggest an insult to energy producing mechanisms. In this study, the absence of histological evidence of toxicity in the locus coeruleus and also in the substantia innominata and in serotonergic cell groups is unlike the more widespread degenerative changes of Parkinson's disease.

摘要

六只成年狨猴接受了多次剂量的1-甲基-4-苯基-1,2,3,6-四氢吡啶(2至13天内总量为8至16毫克/千克),足以引发帕金森综合征,并在3.5个月内被处死。在黑质、腹侧被盖区和下丘脑发现了细胞变化。最早的组织学异常是黑质纹状体轴突近端的轴突肿胀。黑质随后的变化包括尼氏染色减少、细胞体积减小、黑色素颗粒聚集和丢失。其他影响包括核体积和核仁体积减小、细胞耗竭以及胶质细胞增生。细胞质和细胞核萎缩,伊红染色均匀,没有细胞出现细胞质肿胀或包涵体。这些细胞改变,其核变化类似于核溶解,在帕金森病中不会出现,帕金森病的特征是路易小体包涵体和染色质溶解迹象。轴突肿胀的迅速出现、尼氏体的破坏和细胞萎缩表明对能量产生机制的损害。在本研究中,蓝斑以及无名质和血清素能细胞群中没有毒性的组织学证据,这与帕金森病更广泛的退行性变化不同。

相似文献

1
The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.普通狨猴急性给予1-甲基-4-苯基-1,2,3,6-四氢吡啶后神经系统形态学变化的演变与分布
Mov Disord. 1989;4(1):53-74. doi: 10.1002/mds.870040109.
2
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.帕金森病1-甲基-4-苯基-1,2,3,6-四氢吡啶/丙磺舒渐进性神经退行性小鼠模型黑质致密部神经元凋亡的早期迹象。
Neuroscience. 2006 Jun 19;140(1):67-76. doi: 10.1016/j.neuroscience.2006.02.007. Epub 2006 Mar 14.
3
Pathology of MPTP in the marmoset.
Adv Neurol. 1987;45:187-90.
4
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.1-甲基-4-苯基-1,2,3,6-四氢吡啶在动物体内作为帕金森病模型的作用。
J Neural Transm Suppl. 1986;20:11-39.
5
An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.1-甲基-4-苯基-1,2,3,6-四氢吡啶对狨猴急性和长期影响的免疫组织化学研究
Neuroscience. 1987 Dec;23(3):1025-39. doi: 10.1016/0306-4522(87)90178-3.
6
Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.粒细胞-巨噬细胞集落刺激因子可促进1-甲基-4-苯基-1,2,3,6-四氢吡啶诱导的小鼠帕金森病模型中多巴胺能神经元的存活。
Eur J Neurosci. 2009 Mar;29(5):891-900. doi: 10.1111/j.1460-9568.2009.06653.x. Epub 2009 Feb 24.
7
Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.用1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)处理的猴子中的蓝斑病变和嗜酸性包涵体。
Ann Neurol. 1986 Oct;20(4):449-55. doi: 10.1002/ana.410200403.
8
Administration of MPTP to the common marmoset does not alter cortical cholinergic function.给普通狨猴施用1-甲基-4-苯基-1,2,3,6-四氢吡啶不会改变皮质胆碱能功能。
Mov Disord. 1986;1(2):129-34. doi: 10.1002/mds.870010207.
9
Early-stage loss of dopamine uptake-site binding in MPTP-treated monkeys.MPTP 处理的猴子中多巴胺摄取位点结合的早期丧失。
Adv Neurol. 1993;60:34-9.
10
MPTP-induced parkinsonism in the common marmoset: behavioral and biochemical effects.
Adv Neurol. 1987;45:183-6.

引用本文的文献

1
Identifying the dataset to define the optimal timing of histopathological examination for central nervous system toxicity in MPTP-induced Parkinson's disease monkey model.确定数据集以定义MPTP诱导的帕金森病猴模型中中枢神经系统毒性的组织病理学检查的最佳时机。
J Toxicol Pathol. 2023 Oct;36(4):199-204. doi: 10.1293/tox.2023-0010. Epub 2023 May 24.
2
Increased Expression of Alpha-, Beta-, and Gamma-Synucleins in Brainstem Regions of a Non-Human Primate Model of Parkinson's Disease.帕金森病非人灵长类动物模型脑干区域中 Alpha-、Beta-和 Gamma-突触核蛋白表达增加。
Int J Mol Sci. 2022 Aug 2;23(15):8586. doi: 10.3390/ijms23158586.
3
Vocalization development in common marmosets for neurodegenerative translational modeling.
普通狨猴发声发育用于神经退行性疾病转化模型研究
Neurol Res. 2018 Apr;40(4):303-311. doi: 10.1080/01616412.2018.1438226. Epub 2018 Feb 19.
4
Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.慢性 MPTP 给药方案在猴子中的应用:帕金森病多巴胺能和非多巴胺能细胞丧失的模型。
J Neural Transm (Vienna). 2018 Mar;125(3):337-363. doi: 10.1007/s00702-017-1774-z. Epub 2017 Aug 31.
5
Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.MPTP 处理的帕金森病猴腹侧中脑多巴胺能细胞群和丘脑底核去甲肾上腺素能神经支配减少。
Neurobiol Dis. 2017 Apr;100:9-18. doi: 10.1016/j.nbd.2016.12.025. Epub 2016 Dec 30.
6
Modeling Parkinson's disease in monkeys for translational studies, a critical analysis.为转化研究建立猴帕金森病模型:批判性分析。
Exp Neurol. 2014 Jun;256:133-43. doi: 10.1016/j.expneurol.2013.09.014. Epub 2013 Sep 23.
7
Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.代谢型谷氨酸受体 5 拮抗剂可保护 MPTP 处理的猴子中的多巴胺能和去甲肾上腺素能神经元免于退化。
Brain. 2011 Jul;134(Pt 7):2057-73. doi: 10.1093/brain/awr137.
8
Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.追踪帕金森病动物模型中的神经外核退化:寻求有效的治疗策略。
J Neurochem. 2011 Aug;118(3):326-38. doi: 10.1111/j.1471-4159.2011.07320.x. Epub 2011 Jun 17.
9
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.帕金森病动物模型:新型治疗方法的来源和疾病病因的线索。
Br J Pharmacol. 2011 Oct;164(4):1357-91. doi: 10.1111/j.1476-5381.2011.01426.x.
10
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.帕金森病的动物模型:与人类疾病现象学的实证比较。
J Neural Transm (Vienna). 1996;103(8-9):987-1041. doi: 10.1007/BF01291788.